CGEM Cullinan Therapeutics, Inc.
Price Chart
Executive Summary
Cullinan Therapeutics announced that interim Phase 1 data for CLN-978 (CD19xCD3 T cell engager) in RA and SLE will be presented at EULAR (June 3–6, 2026). The abstract reports a favorable safety profile at initial doses, robust B cell depletion, and early signals of clinical activity. No specific efficacy rates, dosing, or financial guidance were disclosed; this is an interim data update with no catalyst for approval or pivotal readout.
Actionable Insight
Watch the EULAR presentation June 3–6 for updated patient numbers and response data. Positive incremental data could de-risk the asset modestly, but this is early Phase 1 — no pivotal catalyst. The 67% win rate on past CGEM calls suggests the stock has been range-bound historically on pipeline news; temper expectations.
Key Facts
- Abstract reports favorable safety profile at initial dose levels for CLN-978 in RA and SLE Phase 1 studies.
- Robust B cell depletion in peripheral blood and tissue observed, with early signals of promising clinical activity.
- Updated data including additional patients to be presented at EULAR Congress June 3–6, 2026, London.
- CLN-978 is a wholly owned, subcutaneously administered CD19xCD3 T cell engager targeting autoimmune diseases.
- No specific efficacy rates, response rates, or quantitative clinical outcomes disclosed in the press release.
Financial Impact
No financial data or guidance disclosed; clinical-stage, no approved product revenue.
Risk Factors
- Interim Phase 1 data may not be confirmed at EULAR or in later cohorts.
- Competition from approved B-cell targeting therapies (e.g., CAR-Ts, bispecifics in autoimmunity) is intense.
- No timeline provided for Phase 2 initiation or regulatory discussions.
- Cullinan has no approved products; clinical-stage biotech with binary pipeline risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3297050 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $12.04 awaiting T+5 | awaiting T+5 | — | $13.70 (+13.79%) |
|
Jun 10, 2026
3d ago
|
Press Release
| $13.20 awaiting T+5 | awaiting T+5 | — | $13.70 (+3.79%) |
|
Jun 8, 2026
5d ago
|
8-K
| $13.51 awaiting T+5 | awaiting T+5 | — | $13.70 (+1.44%) |
|
May 19, 2026
25d ago
|
Press Release
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
May 18, 2026
25d ago
|
8-K
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
May 18, 2026
25d ago
|
Press Release
| $14.18 $15.52 | ▲ +9.49% | ▲ +7.19% | $13.70 (−3.35%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $14.91 $13.44 | ▼ −9.86% | ▼ −8.95% | $13.70 (−8.12%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
|
Feb 24, 2026
15w ago
|
Insider Cluster
| $14.27 $15.73 | ▼ −10.23% | ▼ −11.26% | $13.70 (+3.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access